Cellular mechanisms and the role of cytokines in bone erosions in rheumatoid arthritis

Arthritis and Rheumatism

Volumn 43, Issue 10, 2000, Pages 2143-2151

  Gravallese, Ellen M ^a,b   Goldring, Steven R ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b HARVARD INSTITUTES OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; OSTEOCLAST DIFFERENTIATION FACTOR;

BONE EROSION; BONE REMODELING; CELL ACTIVITY; CELL DIFFERENTIATION; HUMAN; OSTEOCLAST; OSTEOLYSIS; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS;

ARTHRITIS, RHEUMATOID; BONE REMODELING; CYTOKINES; HUMANS;

EID: 0033789358     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/1529-0131(200010)43:10<2143::AID-ANR1>3.0.CO;2-S     Document Type: Review

References (92)

1. Osteoporosis and rheumatic diseases
2. Bone mass measurement and bone metabolism in rheumatoid arthritis: A review
3. Bone disease in rheumatological disorders
4. The progression of erosion and joint space narrowing scores in rheumatoid arthritis during the first twenty-five years of disease
5. Factors predicting outcome of rheumatoid arthritis: Results of a followup study
6. Magnetic resonance imaging in the assessment of rheumatoid arthritis: A comparison with plain film radiographs
7. Magnetic resonance imaging of the wrist in early rheumatoid arthritis reveals a high prevalence of erosions at four months after symptom onset
8. The relationship between synovitis and bone changes in early untreated rheumatoid arthritis: A controlled magnetic resonance imaging study
9. Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist
10. Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate
11. A phase III trial of etanercept vs methotrexate in early rheumatoid arthritis (Enbrel ERA trial)
12. Healing phenomena of erosive changes in rheumatoid arthritis patients undergoing disease-modifying anti-rheumatic drug therapy
13. Long-term prospective trial of low-dose methotrexate in rheumatoid arthritis
14. Osteonal and hemi-osteonal remodeling: The spatial and temporal framework for signal traffic in adult human bone
15. Investigation of the cell lineage in bone using a chimera of chick and quail embryonic tissue
16. Osteopetrosis cured by temporary parabiosis
17. Bone resorption restored in osteopetrotic mice by transplants of normal bone marrow and spleen cells
18. Local and systemic factors in the pathogenesis of osteoporosis
19. Bone marrow, cytokines, and bone remodeling; emerging insights into the pathophysiology of osteoporosis
20. Commitment and differentiation of osteoclast precursor cells by the sequential expression of c-Fms and receptor activator of nuclear factor kappa B (RANK) receptors
21. Sequential expression of phenotype markers for osteoclasts during differentiation of precursors for multinucleated cells formed in long term human marrow cultures
22. Expression of the calcitonin receptor in bone marrow cell cultures and in bone: A specific marker of the differentiated osteoclast that is regulated by calcitonin
23. Osteoclast markers accumulate on cells developing from human peripheral blood mononuclear precursors
24. Modulation of osteoclast differentiation
25. Generation of osteoclastic function in mouse bone marrow cultures: Multinuclearity and tartrate-resistant acid phosphatase are unreliable markers for osteoclastic differentiation
26. Regulation of osteoclast function
27. Differential effects of the 3',5'-cyclic adenosine monophosphate and protein kinase C pathways on the response of isolated rat osteoclasts to calcitonin
28. Cellular and molecular mechanisms in the regulation and function of osteoclasts
29. Calcitonin receptors as markers for osteoclastic differentiation: Correlation between generation of bone-resorptive cells and cells that express calcitonin receptors in mouse bone marrow cultures
30. Osteoclast-like cells in murine collagen induced arthritis
31. Induction of abundant osteoclast-like multinucleated giant cells in adjuvant arthritic rats with accompanying disordered high bone turnover
32. The erosive front: A topographic study of the junction between the pannus and the subchondral plate in the macerated rheumatoid metacarpal head
33. Chondroclasts and osteoclasts at subchondral sites of erosion in the rheumatoid joint
34. Cloning, characterization and expression of a human calcitonin receptor from an ovarian carcinoma cell line
35. Synovial tissue in rheumatoid arthritis is a source of osteoclast differentiation factor
36. Cysteine proteinase cathepsin K mRNA is expressed in synovium of patients with rheumatoid arthritis and is detected at sites of synovial bone destruction
37. Identification of cell types responsible for bone resorption in rheumatoid arthritis and juvenile rheumatoid arthritis
38. Expression of osteoclast differentiation factor at sites of bone erosion in collagen-induced arthritis
39. Expression of two human skeletal calcitonin receptor isoforms cloned from a giant cell tumor of bone
40. The physiology of parathyroid hormone-related protein
41. Parathyroid hormone-related peptide in synovial fluid and disease activity of rheumatoid arthritis
42. Synovium as a source of increased amino-terminal parathyroid hormone-related protein expression in rheumatoid arthritis; a possible role for locally produced parathyroid hormone-related protein in the pathogenesis of rheumatoid arthritis
43. Tumor necrosis factor alpha stimulates osteoclast differentiation by a mechanism independent of the ODF/RANKL-RANK interaction
44. Macrophage colony-stimulating factor stimulates survival and chemotactic behavior in isolated osteoclasts
45. Interleukin 4, interferon-gamma, and prostaglandin E impact the osteoclastic cell-forming potential of murine bone marrow macrophages
46. Cytokines in the pathogenesis of osteoporosis
47. Anti-tumor necrosis factor alpha therapy of rheumatoid arthritis: Mechanism of action
48. Role of cytokines in rheumatoid arthritis
49. Localization of tumor necrosis factor α in synovial tissues and at the cartilage-pannus junction in patients with rheumatoid arthritis
50. Localization of interleukin-1 alpha, type 1 interleukin-1 receptor and interleukin-1 receptor antagonist in the synovial membrane and cartilage/pannus junction in rheumatoid arthritis
51. Constitutive intra-articular expression of human IL-1β following gene transfer to rabbit synovium produces all major pathologies of human rheumatoid arthritis
52. Development of chronic inflammatory arthropathy resembling rheumatoid arthritis in interleukin 1 receptor antagonist-deficient mice
53. Anticytokine treatment of established type II collagen-induced arthritis in DBA/1 mice: A comparative study using anti-TNFα, anti-IL-1 α/β, and IL-1Ra
54. IL-1 alpha beta blockade prevents cartilage and bone destruction in murine type II collagen-induced arthritis, whereas TNF-alpha blockade only ameliorates joint inflammation
55. Suppression of experimental arthritis by gene transfer of interleukin 1 receptor antagonist cDNA
56. Transgenic mice expressing human tumour necrosis factor: A predictive genetic model of arthritis
57. DBA/1 mice expressing the human TNF-alpha transgene develop a severe, erosive arthritis: Characterization of the cytokine cascade and cellular composition
58. Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis
59. Involvement of endogenous tumor necrosis factor alpha and transforming growth factor beta during induction of collagen type II arthritis in mice
60. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL
61. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation
62. The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption
63. Osteoprotegerin production by human osteoblast lineage cells is stimulated by vitamin D, bone morphogenetic protein-2, and cytokines
64. Osteotropic agents regulate the expression of osteoclast differentiation factor and osteoprotegerin in osteoblastic stromal cells
65. A novel molecular mechanism modulating osteoclast differentiation and function
66. TRANCE (tumor necrosis factor [TNF]-related activation-induced cytokine), a new TNF family member predominantly expressed in T cells, is a dendritic cell-specific survival factor
67. A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function
68. TRANCE is a novel ligand of the tumor necrosis factor receptor family that activates c-Jun N-terminal kinase in T cells
69. Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand
70. Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand
71. RANK is the essential signaling receptor for osteoclast differentiation factor in osteoclastogenesis
72. Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): A mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro
73. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis
74. RANK is essential for osteoclast and lymph node development
75. Osteoprotegerin: A novel secreted protein involved in the regulation of bone density
76. Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification
77. Involvement of receptor activator of nuclear factor κB ligand/osteoclast differentiation factor in osteoclastogenesis from synoviocytes in rheumatoid arthritis
78. Activated T lymphocytes support osteoclast formation in vitro
79. Human osteoclast formation and bone resorption by monocytes and synovial macrophages in rheumatoid arthritis
80. T cell interleukin-17 induces stromal cells to produce proinflammatory and hematopoietic cytokines
81. IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis
82. Human interleukin-17: A T cell-derived proinflammatory cytokine produced by the rheumatoid synovium
83. IL-17 is produced by some proinflammatory Th1/Th0 cells but not by Th2 cells
84. A novel role of IL-15 in the development of osteoclasts: Inability to replace its activity with IL-2
85. Interleukin-15 mediates T cell-dependent regulation of tumour necrosis factor-alpha production in rheumatoid arthritis
86. Interleukin 15: A proinflammatory role in rheumatoid arthritis synovitis
87. Interleukin 18 inhibits osteoclast formation via T cell production of granulocyte macrophage colony-stimulating factor
88. NE-58095: A diphosphonate which prevents bone erosion and preserves joint architecture in experimental arthritis
89. Zoledronate (CGP 42'446), a bisphosphonate, protects against metaphyseal intracortical defects in experimental inflammatory arthritis
90. Increased bone mass with pamidronate treatment in rheumatoid arthritis: Results of a three-year randomized, double-blind trial
91. Effect of calcitonin on bone histomorphometry and bone metabolism in rheumatoid arthritis
92. Intranasal calcitonin for the prevention of bone erosion and bone loss in rheumatoid arthritis